[Market Pulse] The Paradox Revealed by the Medicine Shortage Crisis
Essential Medicines Must Be Viewed from a Supply Chain Maintenance Perspective
Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association
View original imageWhat if you could not find a single tube of antibiotic eye ointment necessary for treating a stye at your local pharmacy? What if there was a nationwide shortage of children's fever reducers or antibiotics? While you might experience only occasional inconvenience, if such incidents are repeated, they signal not just a simple out-of-stock issue but a warning sign that threatens public health.
In fact, South Korea is one of the few countries in the world capable of producing a significant portion of the medicines its population needs. This means the country has the capacity to supply essential medicines even during crises such as pandemics or international conflicts. However, the supply of the most basic and essential medicines is increasingly unstable.
The recent shortage of antibiotic eye ointment is a clear example. As manufacturers producing ointments for treating styes and blepharitis have successively withdrawn from the market, the supply structure now relies virtually on a single producer. The recent shortage of children's fever reducers and antibiotics is a similar case. These are indispensable medicines, but due to low profitability and high production burdens, companies have found it difficult to increase production.
We Must Reflect on the Implications of the Eye Ointment Shortage
This phenomenon is not limited to certain products. Supply disruptions are increasing for routine medications like cold medicine, fever reducers, and antibiotics, as well as cancer drugs and treatments for rare diseases. In the past five years, the number of reported cases of production, import, or supply suspension or shortage has exceeded 1,400, which shows that medicine shortages are no longer exceptional events.
The causes are not simple. Various independent factors, such as global supply chain instability, reliance on foreign active pharmaceutical ingredients, stricter quality control standards, and surging demand, have combined to create this problem. However, there is a common underlying reality: Even when essential medicines are produced, it is difficult to secure sufficient profits.
It is necessary to manage drug prices in order to protect the health insurance budget. Using citizens' insurance contributions efficiently is a clear duty of the government. However, one question must be raised here: If, as a result of lowering drug prices to save the insurance budget, people cannot obtain medicines when they need them, what will happen? If a policy aimed at protecting the insurance budget ends up threatening citizens' access to treatment, has not the means and the end become reversed?
Lower Drug Prices Do Not Necessarily Benefit the Public
The government has not been idle. It has made various efforts, such as operating the Exit-Prevention Pharmaceutical System, expanding production support programs, and implementing preferential policies for domestically produced active pharmaceutical ingredients. However, it is clear that decades of accumulated structural problems cannot be solved by merely adjusting certain drug prices.
It is now time to change the question. At least for essential medicines, we should not be asking, "How low can we keep drug prices?" but rather, "How can we maintain supply chains to ensure citizens can access medicines when they need them?"
To achieve this, a new focus on supply stability must be added to price-centered policies. The national system for managing essential medicines should be revamped, and a structure for continuously monitoring the number of production companies and supply risks must be established.
For products with a declining number of manufacturers, the introduction of a joint production platform should also be considered. Civica Rx, a nonprofit pharmaceutical supply platform in the United States, is a good reference case. The government and companies must also actively consider entering into supply stability contracts to maintain a minimum production base.
Medicines are not ordinary consumer goods. While people can wait for delayed delivery of cars or home appliances, treatments must be available precisely when patients need them. The value of medicines lies in their availability at the moment of need. It is important to manage drug prices to protect the insurance budget. However, if citizens cannot obtain medicines, for whom are the savings in the insurance budget?
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.